Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Prostate cancer
Darolutamide (AR antagonist) + ADT drives deep PSA suppression across older/comorbid mHSPC subgroups
Darolutamide (DARO), an androgen receptor inhibitor, was evaluated with androgen deprivation therapy (ADT) vs placebo + ADT in the Phase 3 ARANOTE trial (NCT04736199) in metastatic hormone-sensitive prostate cancer…
NCT04736199 - Trial result
Prostate cancer
BAT (Supraphysiologic Testosterone) + Sipuleucel‑T Drives 100% PA2024 ELISPOT Responses in mCRPC
Bipolar androgen therapy (BAT; testosterone cypionate 400mg IM q4w with ongoing ADT) was given for two cycles before sipuleucel‑T (autologous PAP–GM‑CSF–primed cellular immunotherapy) in a Phase II, Simon two‑stage…
NCT06100705 - Trial result
Prostate cancer
YL201 (B7-H3–targeted ADC) posts 33% ORR and 11.8-mo rPFS in heavily pretreated mCRPC (2.4 mg/kg)
YL201 is an anti-B7H3 antibody–drug conjugate (ADC) evaluated as monotherapy in a Phase 2 study in metastatic castration-resistant prostate cancer after ≥1 androgen receptor axis-targeted therapy (ARAT) and ≤2…
NCT06241846 - Trial result
Prostate cancer
CONV01-α (Ac-225 PSMA–mAb alpha-radioconjugate) drives 45% PSA50 in Lu-PSMA–pretreated mCRPC
Ac-225 rosopatamab tetraxetan (CONV01-α) is an actinium-225 alpha-emitting radionuclide conjugated to a PSMA-targeting monoclonal antibody, evaluated in the Phase 2 CONVERGE-01 Part 3 dose-escalation/initial…
NCT06549465 - Trial result
Prostate cancer
ST-DoxPCa H&E Biomarker Identifies mHSPC Patients Most Likely to Benefit From Docetaxel
ST-DoxPCa is an AI computational pathology biomarker that infers spatial gene-expression patterns from routine H&E to predict docetaxel benefit in metastatic hormone-sensitive prostate cancer, using a Vision…
NCT00309985 - Trial result Spotlight
Head and neck cancer
NBTXR3 (hafnium oxide radioenhancer) + SBRT reirradiation followed by anti–PD-1 drives 48% ORR in recurrent/metastatic HNSCC
NBTXR3 is an intratumoral hafnium oxide nanoparticle “radioenhancer” designed to locally amplify radiation effects and potentially augment immune priming; in Study 1100 (Phase I dose escalation/expansion;…
NCT03589339 - Trial result Spotlight
Head and neck cancer
Pembrolizumab (PD-1) + Definitive RT Improves 2-Year PFS vs Cisplatin CRT in Unfavorable-Risk p16+ HNSCC (KEYCHAIN)
KEYCHAIN was an open-label, randomized Phase II trial across 6 US academic centers testing definitive RT (70 Gy/35 fx) plus concurrent/adjuvant pembrolizumab (anti–PD-1; 200 mg starting 2 weeks pre-RT, then q3w up to…
- Trial result Spotlight
Head and neck cancer
Tosposertib (TGFβRI/VEGFR2 inhibitor) + pembrolizumab drives 75% ORR in 1L R/M HNSCC
Tosposertib (TU2218) is an oral dual TGFβRI/ALK5 and VEGFR2 inhibitor designed to counter TGF-β–mediated immune exclusion and angiogenesis, here combined with pembrolizumab (anti–PD-1) in an open-label, multicenter,…
NCT05784688 - Trial result Spotlight
Head and neck cancer
Ficerafusp alfa (EGFR×TGF-β trap) + pembrolizumab drives deeper shrinkage and ~10-mo mPFS in 1L HPV− R/M HNSCC
Ficerafusp alfa (BCA101) is a bifunctional EGFR-directed antibody engineered to trap TGF-β, combined here with pembrolizumab (anti–PD-1) in two Phase 1/1b first-line dose-expansion cohorts for PD-L1 CPS≥1,…
NCT04429542 - Trial result
Head and neck cancer
Pembrolizumab (PD-1) + definitive CRT improves 5-year EFS in PD-L1 CPS≥10 unresected LA HNSCC
Pembrolizumab is a PD-1 checkpoint inhibitor added concurrently to definitive cisplatin-based chemoradiotherapy (CRT) and continued as maintenance (17 total q3w cycles) in the randomized, double-blind Phase 3…
NCT03040999 - Trial result
Head and neck cancer
ASP-1929 (EGFR–IR700 photoimmunotherapy) lifts OS to 15.7mo vs 9.6mo in heavily pretreated recurrent HNSCC, but underpowered
ASP-1929 photoimmunotherapy (PIT) is an anti‑EGFR monoclonal antibody–IR700 dye conjugate activated by 690nm light to cause localized tumor cell kill (and potentially immune priming); it was tested in a global Phase…
NCT03769506 - Trial result
Head and neck cancer
VV1 (VSV‑IFNβ‑NIS) intratumoral oncolytic virus + PD‑1 blockade (cemiplimab) hits 30% ORR in 1L R/M HNSCC (Simon’s stage 1)
VV1 is an intratumoral oncolytic vesicular stomatitis virus engineered to express IFNβ and NIS (VSV‑IFNβ‑NIS), combined here with the anti–PD‑1 antibody cemiplimab in a Phase 2, Simon two-stage, first-line…
NCT04291105 - Trial result
Head and neck cancer
Metronomic carboplatin/paclitaxel + PD-1 blocker cemiplimab delivers 42.5% ORR (15% CR) in 1L R/M HNSCC, with cytokine shifts tied to outcome
Cemiplimab is an anti–PD-1 monoclonal antibody combined here with metronomic weekly carboplatin (AUC1) and paclitaxel (25 mg/m²) to potentially retain chemo–immune priming with less toxicity than standard-dose…
NCT04862650 - Trial result
Head and neck cancer
Cemiplimab (PD-1) + cisplatin/docetaxel induction delivers 83% ORR in stage IV LA SCCHN (Phase 1)
Cemiplimab is an anti–PD-1 checkpoint inhibitor combined here with induction cisplatin + docetaxel (TP) ahead of definitive standard-of-care surgery and/or concurrent chemoradiation, followed by adjuvant cemiplimab,…
NCT05376553 - Trial result
Head and neck cancer
Cetuximab (EGFR IgG1) After PD-1 Failure Delivers 33% PR Rate in R/M HNSCC
Cetuximab is an EGFR-targeting IgG1 monoclonal antibody with potential immune-effector activity, evaluated as monotherapy in a non-randomized, single-institution cohort of recurrent/metastatic HNSCC progressing on or…
NCT04375384 - New trial
Prostate cancer
Phase 2 ADT + ARPI androgen-receptor signaling inhibition with risk-adapted de-escalation in mHSPC
Georgetown University and the MedStar Health network are running this prospective, interventional, non-randomized Phase 2 pragmatic study (up to 108 patients) to test whether a risk-adapted intensification strategy…
NCT07645326 Exploratory - New trial
Prostate cancer
Phase 2 MR-guided SBRT uses MR-Linac image guidance (no drug; radiation dose de-escalation).
This Memorial Sloan Kettering Cancer Center–sponsored Phase 2 randomized trial (DESTINATION 2) tests whether *intra-prostatic dose de-escalation* can reduce urinary/bowel side effects while preserving tumor control…
NCT07635238 Exploratory - New trial
Prostate cancer
Phase 2 sacituzumab tirumotecan TROP2-directed ADC (topoisomerase I payload) in post-platinum NEPC.
This Phase 2, open-label, single-arm study tests sacituzumab tirumotecan (a TROP2-targeting monoclonal antibody–drug conjugate carrying a belotecan-derived topoisomerase I inhibitor payload) in metastatic…
NCT07639086 Exploratory - New trial
Prostate cancer
Phase 2 61Cu-NU101 PSMA-targeted PET radiotracer (PSMA ligand) vs Pylarify in prostate cancer
This Phase 2, two-center, single-arm diagnostic comparison study tests whether the investigational PET radiotracer 61Cu-noDAGa-PSMA I&T (61Cu-NU101) can match or outperform the current standard 18F-piflufolastat…
NCT07635524 Exploratory - New trial
Prostate cancer
Phase 2 Microboost SBRT focal SIB (DNA damage via ionizing radiation) with whole-gland de-escalation
Georgetown University’s Phase 2 MIDAS trial tests whether MRI-defined “microboost” SBRT can safely intensify dose to up to 4 intraprostatic lesions (45 Gy in 5 fractions) while de-escalating dose to the remainder of…
NCT07644598 Exploratory - New trial
Prostate cancer
Phase 1/2 GDC-1261 trial in prostate cancer; no disclosed MOA/target.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07567846 First-in-human - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 FH-WT1-E50 WT1-targeted TCR‑T plus azacitidine for MRD+ AML
This Phase 1 study at Fred Hutchinson Cancer Center evaluates FH‑WT1‑E50, an autologous CD4+/CD8+ T-cell product genetically transduced to express an HLA‑A02:01–restricted, WT1-specific T-cell receptor (TCR‑T; MOA:…
NCT07645469 First-in-human - New trial
Other blood cancers and transplant
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT.
Stanford University is running this non-randomized, open-label Phase 2 study to confirm feasibility and safety of an automated total marrow and lymphoid irradiation (TMLI) platform when embedded into a previously…
NCT07634536 Exploratory - New trial
Other blood cancers and transplant
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL
No disclosed MOA. We do not include details of trials without this basic information.
NCT07572006 First-in-human - New trial
Lymphoma
Phase 1 axatilimab CSF1R-blocking monoclonal antibody conditions macrophages alongside commercial CAR-T.
This open-label Phase 1 study (“MAC-SHIFT”) at Northside Hospital evaluates whether adding axatilimab—a CSF1R-directed monoclonal antibody that inhibits macrophage/monocyte CSF-1R signaling and can reduce…
NCT07638982 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 2 AUR103 calcium oral CD47 antagonist tests innate-immunity reactivation in NETs.
This proof-of-concept, open-label Phase 2 study (BHARAT-3) evaluates single-agent AUR103 calcium—an orally bioavailable small-molecule CD47 antagonist that aims to block the “don’t-eat-me” signal and promote…
NCT07640737 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 CIML-NK allogeneic NK-cell immunotherapy (IL-12/15/18–primed “memory-like” NK cells)
This first-in-human, single-site Phase 1 study at Cincinnati Children’s tests whether cytokine-induced memory-like natural killer cells (CIML-NK)—an allogeneic NK-cell product generated from a patient’s…
NCT07635056 First-in-human - New trial
Sarcoma and GIST
Phase 1b REC-617 selective CDK7 inhibitor (transcription/cell-cycle kinase target) in RB1– LMS
MD Anderson Cancer Center is running this Phase 1b, single-group, open-label study to test whether REC-617—an oral small-molecule inhibitor of CDK7 (a cyclin-dependent kinase that supports transcriptional regulation…
NCT07633756 Exploratory - New trial Spotlight
Ovarian cancer
Phase 1 GB-5267 IL-18–armored anti-MUC16 CAR T cell therapy in platinum-resistant ovarian cancer.
This first-in-human, open-label Phase 1 dose-escalation study tests GB-5267, an autologous CAR T-cell product engineered to recognize MUC16 (a surface antigen commonly expressed in epithelial ovarian cancers) and…
NCT07489287 First-in-human - New trial
Ovarian cancer
Phase 2 pembrolizumab PD-1 antibody plus TLR3 agonist rintatolimod and autologous αDC1 vaccine
This Phase 2, nonrandomized, sequential-design neoadjuvant study at UPMC Hillman Cancer Center tests whether “locoregional chemoimmunotherapy” can improve immune activation and clinical outcomes in chemo-naive stage…
NCT07634094 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.